PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).
Lauren C. Harshman(Dana-Farber Cancer Institute), Bradley C. Leibovich(Mayo Clinic in Arizona), Anil Kapoor(People’s University), Michael A.S. Jewett(Princess Margaret Cancer Centre), Viraj A. Master(Emory University), Brian Shuch(University of California, Los Angeles), Mohamad E. Allaf(Johns Hopkins University), M. Dror Michaelson(Harvard University), Charles G. Drake(Columbia University Irving Medical Center), David Cella(Northwestern University), Naomi B. Haas(University of Pennsylvania), Sabina Signoretti(Brigham and Women's Hospital), Toni K. Choueiri(Harvard University), Mäneka Puligandla(Dana-Farber Cancer Institute), Primo N. Lara(UC Davis Comprehensive Cancer Center), Rajan T. Gupta(Duke University), David F. McDermott(Beth Israel Deaconess Medical Center), Deb Maskens, Michael A. Carducci(Sidney Kimmel Comprehensive Cancer Center), Daniel Yick Chin Heng(University of Calgary)
Cited by 7
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
The Immune Landscape of Cancer
|Immunity|2018|6.3k
The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008
|Journal of Clinical Epidemiology|2010|5.1k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k